BioStem Technologies, Inc. (BSEM) FinancialsBSEMBioStem Technologies, Inc.

BioStem Technologies, Inc. (BSEM) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Hospital, accounting for 87.4% of total sales, equivalent to $5.36M. Another important revenue stream is Physician office. Understanding this composition is critical for investors evaluating how BSEM navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, BioStem Technologies, Inc. maintains a gross margin of 52.55%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -106.35%, while the net margin is -113.57%. These profitability ratios, combined with a Return on Equity (ROE) of -74.74%, provide a clear picture of how effectively BSEM converts its operational activities into shareholder value.

In the context of the broader market, BSEM competes directly with industry leaders such as IGC and QNTM. With a market capitalization of $20.96M, it holds a significant position in the sector. When comparing efficiency, BSEM's gross margin of 52.55% stands against IGC's 18.60% and QNTM's N/A. Such benchmarking helps identify whether BioStem Technologies, Inc. is trading at a premium or discount relative to its financial performance.

BSEM's financial performance has deteriorated significantly, with total revenue dropping from $22,641,720 in Q4 2024 to only $6,135,530 in Q1 2026. The gross margin has also halved to 52.55% in Q2 2026, down from 84.16% in Q4 2024.